ERβ regulates NSCLC phenotypes by controlling oncogenic RAS signaling

Molecular Cancer Research

Volumn 12, Issue 6, 2014, Pages 843-854

  Nikolos, Fotis ^a   Thomas, Christoforos ^a   Rajapaksa, Gayani ^a   Bado, Igor ^a   Gustafsson, Jan Ak̊e ^a  

^a University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BIM PROTEIN; CASPASE 3; CASPASE 7; CYCLIN D2; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21; PROTEIN P27; RAS PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR BETA; HUMANS; LUNG NEOPLASMS; PHENOTYPE; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84902652353     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0663     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6. (Pubitemid 32911406)
2. Albain KS, Unger J, Gotay CC, Davies AM, Edelman M, Herbst RS, et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 2007;25:7549.
3. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small cell lung cancer in women. J Clin Oncol 2007;25:5785-92.
4. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008;14:4417-26.
5. Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 2008;15:475- 83.
6. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11:597-608.
7. Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. Estrogen receptor beta (ERbeta) subtype-specifi c ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009;116:102-9.
8. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005;11:5084-9. (Pubitemid 41003691)
9. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27: 411-7.
10. Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 2011;71:350-5.
11. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005;11: 7280-7. (Pubitemid 41507685)
12. Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2009;23:146-56.
13. Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non -small cell lung cancer. Hum Pathol 2010;41:190- 8.
14. Skov BG, Fischer BM, Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008;59:88-94.
15. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-7.
16. Putnam EA, Yen N, Gallick GE, Steck PA, Fang K, Akpakip B, et al. Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer. Surg Oncol 1992;1: 49-60.
17. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54. (Pubitemid 40637826)
18. Seidel D, Zander T, Heukamp LC, Peifer M, Bos M, Fernández- CuestaL, et al. A genomics-based classification of human lung tumors. Sci Transl Med 2013;5:209ra153.
19. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
20. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457-67.
21. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374- 9.
22. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-9. (Pubitemid 40188446)
23. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Strom A, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009;69:6100-6.
24. Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, et al. ERbeta1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res 2012;14: R148.
25. Karachaliou N, Mayo C, Costa C, Magri I, Gimenez-Capitan A, Molina- Vila MA, et al. KRAS mutations in lung cancer. Clin Lung Cancer 2013;14:205-14.
26. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer. Nat Rev Cancer 2010;10: 760-74.
27. Dey P, Jonsson P, Hartman J, Williams C, Strom A, Gustafsson JA. Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012;26:1991-2003.
28. Thomas CG, Strom A, Lindberg K, Gustafsson JA. Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res Treat 2011;127:417-27.
29. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell-cycle regulators and beyond. Dev Cell 2008;14:159-69. (Pubitemid 351189186)
30. Omoto Y, Imamov O, Warner M, Gustafsson JA. Estrogen receptor alpha and imprinting of the neonatal mouse ventral prostate by estrogen. Proc Natl Acad Sci U S A 2005;102:1484-9. (Pubitemid 40214366)
31. Kapp FG, Sommer A, Kiefer T, Dolken G, Haendler B. 5-alpha-reductase type I (SRD5A1) is upregulated in non-small cell lung cancer but does not impact proliferation, cell-cycle distribution, or apoptosis. Cancer Cell Int 2012;12:1.
32. Dey P, Strom A, Gustafsson JA. Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene. 2013 Sep 30. [Epub ahead of print].
33. Treeck O, Lattrich C, Springwald A, Ortmann O. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 2010;120:557-65.
34. Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7perform distinct, nonredundant roles during the demolition phase of apoptosis. J Biol Chem 2001;276:7320-6.
35. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000;275:18527-33. (Pubitemid 30414814)
36. Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao Y, et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med 2011;17:708-14.
37. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4: 1681-89.
38. Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 2008;30: 415-25. (Pubitemid 351672377)
39. Toulany M, Baumann M, Rodemann HP. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 2007;5:863-72. (Pubitemid 47294813)
40. Er EE, Mendoza MC, Mackey AM, Rameh LE, Blenis J. AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci Signal 2013;6:ra45.
41. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455: 679-83.
42. Alamgeer M, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol 2013;13:394-401.
43. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post hoc analysis of a randomised controlled trial. Lancet 2009;374: 1243-51.
44. (NCBI) TNCfBI. Available from: http://www.ncbi.nlm.nih.gov/UniGene/ESTPro fileViewer.cgi?uglist=Hs.660607.
45. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15:5359-68.
46. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005;25:4693- 8.
47. Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 1999;3:513-9. (Pubitemid 29292608)
48. Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol 2013;24:2080-7.
49. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, et al. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 2010;17:675-89.
50. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35.